anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain an enhancer for the γδT cell activity having the injuring activity for cancer cells without adverse effects, capable of protecting a organism from tumors, excellent in safety and immune responsiveness and useful for medicines, foods, beverages, feeds, etc., by making the enhancer include an extract from a mycelium of Lentinus edodes Sing. SOLUTION: This enhancer contains an extract from a mycelium of Lentinus edodes Sing. obtained by pulverizing and degrading the mycelium prepared by inoculating a fungus of the Lentinus edodes Sing. into a solid culture medium containing, e.g. bagasse and a defatted rice bran as a substrate and culturing the fungus, preferably the solid culture medium containing the mycelium in the presence of water and a enzyme such as a cellulase, a protease or a glucosidase. The enhancer for the γδT cell activity is used for oral administration, parenteral injection or percutaneous absorption and is capable of activating the γδT cell collected from a patient in vitro and used for preventing and treating tumors, bacterial infection, viral infection, etc. The daily dose thereof is preferably within the range of 3,000-4,500 mg.
This study will investigate the use of projection reconstruction dynamic contrast-enhanced MRI (DCE-MRI) as a surrogate marker of tumor vascularity in patients treated with the antiangiogenic agent bevacizumab. DCE-MRI is gaining popularity as a method to assess the functional response of tumors to agents targeting the vascular endothelial growth factor (VGEF) pathways. DCE-MRI measurements have been proposed as a non-invasive measure of both tumor biologic activity and (in the case of antivascular therapy) early response to treatment. A number of phase I and II studies demonstrate the ability for DCE-MRI to detect perfusion changes associated with tumor biologic response to vascularly targeted agents. It has been suggested that pre-treatment DCE-MRI might identify tumors with high intrinsic perfusion and that these tumors will be more likely to respond to antivascular-based therapies. However, the current use of DCE-MRI in clinical settings is challenging. Trade-offs between spatial coverage, time, and spatial resolution make this technique difficult to implement in human studies and may limit its reliability. The use of projection reconstruction-based acquisition can mitigate the need for these trade-offs and can simultaneously provide high temporal and spatial resolution data for DCE-MRI analysis.
AZT is effective in reducing mortality in patients with AIDS who receive the drug after the first episode of Pneumocystis carinii pneumonia (PCP) and in patients with advanced ARC. However, AZT therapy has been associated with significant toxicities. In addition, the effectiveness of AZT appears to decrease during the second and third years of therapy. For these reasons, the development of alternative therapy that would be at least as effective but less toxic is of great importance. The drug ddI is an antiviral agent that inhibits replication of HIV with less apparent toxicity than AZT. Studies indicate that ddI remains active in the body for at least 12 hours; thus benefits of ddI might be achieved with a low frequency of drug administration.

Two dose levels of ddI, each adjusted depending on patient's weight at study entry, are compared with a variable dosage regimen of AZT (the dose which the patient is tolerating at the time of study entry). Randomization is stratified by baseline CD4 cell count (less than 100 or 100-300) and Medical Center. This study continues for at least 12 months after the entry of the first subject. Patients randomized to AZT will receive orally. All patients randomized to AZT also receive a ddI placebo at 12 hour intervals. Patients randomized to ddI receive AZT placebo.
Multifunctional wireless apparatus, spectrometry instruments, real-time computational system and device ergonomic forms for live and telemetry monitoring of clinical parameters, health data and other vital medical information. Clinical parameters and medical information include pulse rate, respiratory rate, continuous blood glucose levels, continuous blood pressure levels, pulse rate variability, oxygen saturation ratio, body temperature, bio-electrical activity, sleep patterns, sleep health and other vital bio-signal data. The telemetry apparatus encompasses electrical and optical spectrometer instruments. The spectrometer designs and its accompanying circuit design ensure that device is bio-safe, lightweight, low-powered and portable. The bio sensor configuration, comprehensive hardware design, computational process and ergonomic design enables the measurement with more accuracy and efficiency, even in movement artefact prone conditions. The system design also assures that the computational process is real-time, faster and low powered. The wireless apparatus keeps track of the user information on daily diet pattern, fluid and water intake, exercise intensity, other essential health data, and provides necessary alerts. The apparatus yields persona-oriented stress levels and helps the user manage stress through guided practices. The health management system functions based on the user inputs and previously computed parameters. An automated life-support functionality is integrated in the system, that can forecast chronic clinical conditions and health risks like sleep apnea, hypertension, hypoglycemia, hyperglycemia, hypothermia, hyperthermia, CO poisoning, fatigue conditions and more.
PURPOSE: A composition containing ibandronic acid or pharmaceutically acceptable salt thereof or vitamin D is provided to minimize the difference of physical property and to ensure uniform physiological effect. CONSTITUTION: A composition for preventing or treating osteoposis contains ibandronic acid, pharmaceutically acceptable salt or hydrate thereof, and vitamin D. The composition is a table. The composition further contains excipient, lubricant, or disintegrant. The pharmaceutically acceptable salt is ammonium salt, alkali metal salt, alkaline earth metal salt, or amino acid salt. The vitamin D is cholecalciferol, calcifediol, calcitriol, or ergocalciferol. The content of vitamin D is 12,000IU-36,000IU.
RATIONALE AND OBJECTIVES: To develop a magnetic resonance imaging (MRI)-based radiomics model for preoperative prediction of lateral pelvic lymph node (LPLN) metastasis (LPLNM) in patients with locally advanced rectal cancer MATERIALS AND METHODS: We retrospectively enrolled 263 patients with rectal cancer who underwent total mesorectal excision and LPLN dissection. Radiomics features from the primary lesion and LPLNs on baseline MRI images were utilized to construct a radiomics model, and their radiomics scores were combined to develop a radiomics scoring system. A clinical prediction model was developed using logistic regression. A hybrid predicting model was created through multivariable logistic regression analysis, integrating the radiomics score with significant clinical risk factors (baseline Carcinoembryonic Antigen (CEA), clinical circumferential resection margin status, and the short axis diameter of LPLN). This hybrid model was presented with a hybrid clinical-radiomics nomogram, and its calibration, discrimination, and clinical usefulness were assessed.
RESULTS: A total of 148 patients were included in the analysis and randomly divided into a training cohort (n = 104) and an independent internal testing cohort (n = 44). The hybrid clinical-radiomics model exhibited the highest discrimination, with an area under the receiver operating characteristic (AUC) of 0.843 [95% confidence interval (CI), 0.706-0.968] in the testing cohort compared to the clinical model [AUC (95% CI) = 0.772 (0.589-0.856)] and radiomics model [AUC (95% CI) = 0.731 (0.613-0.849)]. The hybrid prediction model also demonstrated good calibration, and decision curve analysis confirmed its clinical usefulness.
CONCLUSION: This study developed a hybrid MRI-based radiomics model that incorporates a combination of radiomics score and significant clinical risk factors. The proposed model holds promise for individualized preoperative prediction of LPLNM in patients with locally advanced rectal cancer.
DATA AVAILABILITY STATEMENT: The data presented in this study are available on request from the corresponding author.
Respiratory depression is the primary risk of morphine sulfate injection. Respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation. Morphine administration should be limited to use by those familiar with the management of respiratory depression. Rapid intravenous administration may result in chest wall rigidity.

Patients with chronic obstructive pulmonary disease or cor pulmonale and in patients having a substantially decreased respiratory reserve (e.g., severe kyphoscoliosis), hypoxia, hypercapnia, or preexisting respiratory depression have an increased risk of increased airway resistance and decrease respiratory drive to the point of apnea with use of morphine sulfate injection. Therefore, consider alternative non-opioid analgesics, and use morphine sulfate injection only under careful medical supervision at the lowest effective dose in such patients.
Magnetotherapeutic apparatus for generating acoustically modulating electromagnetic field contains the digital player, two individual electroacoustic emitters with regulator of output voltage from player, and electronic unit with two circuits controlled by the same player. The first circuit contains the preamplifier with the connector for the individual electroacoustic emitters, output amplifier and dynamic head for group listening of phonograms. The second circuit contains the preamplifier, the amplifier and electric adapter for increasing voltage and output of the electric signal from amplifier with the connector for the inducer of the electromagnetic field. Both circuits have two poser supplies. The first power supply produces bidirectional voltage of ±5 V supplied to preamplifiers. The second power supply produces bidirectional voltage of ±15 V supplied to amplifiers. The power supplies are connected to the source of alternate current.
PURPOSE:To restrict orientation of protein for the inside and outside of membrane of vesicles by forming a layer of molecules contg. a protein on an interface between gas and liquid of a liquid suspension of membrane vesicles, and introducing the protein in the layer of the molecules into the membrane vesicles contacting with the layer of the molecules by setting a surface pressure of the layer of the molecules at a high pressure. CONSTITUTION:A layer 10 of molecules contg. a protein is formed on an interface between gas and liquid of a liquid suspension of membrane vesicles comprising a liposome consisting singly of a lipid or a proteoliposome contg. a protein. Then, the protein in the layer of the molecules is introduced into the membrane vesicles contacting with the layer of molecules by setting the surface pressure of the layer of molecules at a high pressure, for example, by moving a separating plate 20. Thus, the orientation of protein for the inside and outside of the membrane of the vesicules can be controlled in a stage of forming a proteoliposome by introducing a protein into a liposome.
Long QT Syndrome type 8 (LQT8) is a cardiac arrhythmic disorder associated with Timothy Syndrome, stemming from mutations in the CACNA1C gene, particularly the G406R mutation. While prior studies hint at CACNA1C mutations' role in ventricular arrhythmia genesis, the mechanisms, especially in G406R presence, are not fully understood. This computational study explores how the G406R mutation, causing increased transmural dispersion of repolarization, induces and sustains reentrant ventricular arrhythmias. Using three-dimensional numerical simulations on an idealized left-ventricular model, integrating the Bidomain equations with the ten Tusscher-Panfilov ionic model, we observe that G406R mutation with 11% and 50% heterozygosis significantly increases transmural dispersion of repolarization. During S1-S4 stimulation protocols, these gradients facilitate conduction blocks, triggering reentrant ventricular tachycardia. Sustained reentry pathways occur only with G406R mutation at 50% heterozygosis, while neglecting transmural heterogeneities of action potential duration prevents stable reentry, regardless of G406R mutation presence.
Cetuximab will be administered at the dose of 500 mg/m2 intravenously (IV) over 120 minutes, followed by 500 mg/m2 every 2 weeks, IV over 2 hours at an infusion rate not to exceed 5 ml/min. Followed immediately by Irinotecan administered at a dose of 180 mg/m2 IV over 60 minutes every two weeks.
An increasingly popular scheme for poverty alleviation is microcredit, the awarding of small loans to individuals too poor or too remote to take advantage of traditional lending services. Studies have repeatedly shown that income is one of the factors strongly associated with physical and mental wellbeing. Yet economic growth alone doesn't necessarily lead to healthier families, especially if basic health knowledge or health services are absent in the community. Microcredit institutions have recently tried to address this issue by supplementing banking-only microcredit programs with programs that include "tie-ins" or "add-ons" such as health education or health services. A rigorous evaluation of such "banking-plus" endeavors has not yet been conducted, leaving a gap in the knowledge base regarding whether these organizations are meeting their stated goals in catering to both economic and social needs. This study attempts to address this research question using a randomized controlled trial of a health education intervention to clients of a microcredit organization in Peru.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely ophthalmology and aims at surgical management of the patients with primary glaucoma of eyes with cataract. That is ensured by cataract phacoemulsification and implantation of an IOL. It is followed by inducing miosis, and a physiologic saline jet is directed on a trabecular zone along the whole circular length, and the content of an anterior chamber is non-contact aspirated simultaneously. After that, a proteolytic enzyme is introduced in the anterior chamber in a dose sufficient to destruct fibronectin and adhesive proteins. Hemase may be used as a proteolytic enzyme. ^ EFFECT: method provides stable and adequate improvement of intraocular pressure and fluid outflow in a drainage system with reduced injures accompanying a combined operation in the patients with primary compensated or subcompensated glaucoma combined with cataract. ^ 3 cl, 1 ex
BACKGROUND: Postpartum vulvovaginal hematoma is a complication of vaginal delivery that may progress to life-threatening conditions. However, the management of hematomas, including conservative therapy, surgery, and arterial embolization, is yet to be standardized.
OBJECTIVE: This study aimed to: (1) evaluate hematoma features that can be treated conservatively, and (2) determine whether surgery or transcatheter arterial embolization is superior in reducing blood transfusion.
STUDY DESIGN: This cross-sectional study included postpartum women transferred to Tohoku University Hospital, Japan, between January 2016 and September 2023 for postpartum vulvovaginal hematomas. Notably, all patients except 1 underwent contrast-enhanced computed tomography. The patients were classified into the following groups: (1) the conservative group who received neither surgery nor transcatheter arterial embolization and (2) the therapeutic intervention group who received surgery or transcatheter arterial embolization. The primary analysis included all patients. Variables for the choice of therapeutic intervention, including the shock index, hemoglobin concentration at arrival, hematoma size, and presence of extravasation, were assessed using a modified Poisson regression model. The secondary analysis included patients who received therapeutic intervention (ie, surgery or transcatheter arterial embolization). Variables for estimating the total amount of blood transfusion, including shock index, hemoglobin concentration at arrival, hematoma size, type of intervention, and presence of extravasation, were analyzed using multiple linear regression.
RESULTS: Fifty-seven cases were included in this study. Patients underwent conservative treatment (n=19), surgery (n=11), or transcatheter arterial embolization (n=27). In primary analysis, only the presence of extravasation was significantly associated with the choice of therapeutic intervention (adjusted risk ratio [95% confidence interval], 5.30 [1.53-18.37]). In the secondary analysis, the choice of surgery as a therapeutic option (unstandardized coefficient [95% confidence interval], 4.64 [1.15-8.13]; reference: transcatheter arterial embolization), lower hemoglobin concentration at arrival (-2.84 [-4.71 to -0.97]; 1 g/dL increment), and larger hematoma size (3.38 [1.23-5.53]; 100 cm3 increments) were significantly associated with increased blood transfusion.
CONCLUSION: When a vulvovaginal hematoma does not exhibit extravasation, it can be treated conservatively regardless of size. When a therapeutic intervention is selected, transcatheter arterial embolization reduces the total amount of blood transfusion compared with surgery.
The Human Genome Project, completed in 2003, heralded a new era in precision medicine. Somewhat tempering the excitement of the elucidation of the human genome is the emerging recognition that there are fewer single gene disorders than first anticipated, with most diseases predicted to be polygenic or at least gene-environment modified. Hereditary haemochromatosis (HH) is an inherited iron overload disorder, for which the vast majority of affected individuals (>90%) have homozygosity for a single pathogenic variant in the HFE gene, resulting in p.Cys282Tyr. Further, there is significant benefit to an individual in identifying the genetic risk of HH, since the condition evolves over decades, and the opportunity to intervene and prevent disease is both simple and highly effective through regular venesection. Add to that the immediate benefit to society of an increased pool of ready blood donors (blood obtained from HH venesections can generally be used for donation), and the case for population screening to identify those genetically at risk for HH becomes more cogent. Concerns about genetic discrimination, creating a cohort of "worried well", antipathy to acting on medical advice to undertake preventive venesection or simply not understanding the genetic risk of the condition adequately have all been allayed by a number of investigations. So why then has HH population genetic screening not been routinely implemented anywhere in the world? The answer is complex, but in this article we explore the pros and cons of screening for HH and the different views regarding whether it should be phenotypic (screening for iron overload by serum ferritin and/or transferrin saturation) or genotypic (testing for HFE p.Cys282Tyr). We argue that now is the time to give this poster child for population genetic screening the due consideration required to benefit the millions of individuals at risk of HFE-related iron overload.
Patients will receive study medication colchicine 0.5 mg every 8 hours for 3 days (PO), followed by 4 weeks (+/-7 days) 0.5 mg twice daily. If a dose is missed, it should not be replaced.
Cardiac Resynchronization Therapy (CRT) has emerged as a promising therapeutic addition in patients with drug refractory heart failure (HF). Along with providing relief of symptoms of HF, cardiac resynchronization therapy defibrillators (CRT-D) are used for the prevention of sudden cardiac death (SCD). Although there are concerns that the defibrillation threshold (DFT) estimates are elevated in the heart failure (HF) patient population due to lower LV ejection fraction (EF) and left ventricular (LV) dysfunction, there is paucity of data available to evaluate this theory.

Recently, two different studies in a retrospective manner evaluated the energy requirements in patients receiving cardiac resynchronization therapy defibrillators (CRT-D). Burke et al analyzed DFTs in 50 patients each implanted with a cardiac resynchronization therapy defibrillators (CRT-D) device and an implantable cardioverter defibrillator (ICD). Although the ejection fraction (EF) in cardiac resynchronization therapy defibrillators (CRT- D) group was lower than the implantable cardioverter defibrillator (ICD) group, the mean defibrillation thresholds (DFTs) between the two groups were not significantly different (10.2 ± 6.1 J for the cardiac resynchronization therapy (CRT) group vs. 9.5 ± 5.0 J for the control group)14. In the ASSURE study, Doshi et al. showed that patients receiving cardiac resynchronization therapy defibrillators (CRT-D) devices do not have higher energy requirements when compared to patients receiving modern single or dual chamber implantable cardioverter defibrillators (ICDs). Although, there was a trend toward higher energy requirements found among patients with higher degrees of heart failure.

Major cardiac resynchronization therapy (CRT) trials have showed that cardiac resynchronization therapy (CRT) therapy has positive effects on ejection fraction (EF) and the heart failure (HF) condition of the patient over time. But, there is no study that has evaluated the defibrillation thresholds (DFTs) in the heart failure (HF) patients over time of receiving cardiac resynchronization therapy (CRT). This information will help the clinicians decide if they need to perform more invasive procedures during device implant to lower DFTs in patients who do not meet the defibrillation safety margin or they should just wait over time for the CRT to reduce the defibrillation threshold (DFT). Also, there is no published data about the stability of defibrillation thresholds (DFTs) in heart failure (HF) patients over time. The results from this study will also help to clarify whether it is safe to never test the defibrillation thresholds (DFTs) post-implant in this patient population.
Study participants will complete an 80 case learning set followed by a 20-case post test. The study intervention in this group is a 20-case test at 12 months.
Kidney stones are a common urological disease with an increasing incidence worldwide. Traditional diagnostic methods for kidney stones are relatively complex and time-consuming, thus necessitating the development of a quicker and simpler diagnostic approach. This study investigates the clinical screening of kidney stones using Surface-Enhanced Raman Scattering (SERS) technology combined with multivariate statistical algorithms, comparing the classification performance of three algorithms (PCA-LDA, PCA-LR, PCA-SVM). Urine samples from 32 kidney stone patients, 30 patients with other urinary stones, and 36 healthy individuals were analyzed. SERS spectra data were collected in the range of 450-1800 cm-1 and analyzed. The results showed that the PCA-SVM algorithm had the highest classification accuracy, with 92.9 % for distinguishing kidney stone patients from healthy individuals and 92 % for distinguishing kidney stone patients from those with other urinary stones. In comparison, the classification accuracy of PCA-LR and PCA-LDA was slightly lower. The findings indicate that SERS combined with PCA-SVM demonstrates excellent performance in the clinical screening of kidney stones and has potential for practical clinical application. Future research can further optimize SERS technology and algorithms to enhance their stability and accuracy, and expand the sample size to verify their applicability across different populations. Overall, this study provides a new method for the rapid diagnosis of kidney stones, which is expected to play an important role in clinical diagnostics.